Hologic has acquired molecular diagnostic assays and epigenetics products manufacturer Diagenode in a deal worth approximately $159m.
The acquisition will expand Hologic’s diagnostic business across test menu, customer segments, and geography.
Go deeper with GlobalData
Diagenode offers more than 30 CE-marked real-time polymerase chain reaction (PCR) tests for detecting bacteria, parasites, and viruses linked to sexually transmitted infections, respiratory diseases, meningitis, and gastroenteritis.
Hologic international group president Jan Verstreken said: “Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu.
“Diagenode has been a great partner since 2016, helping us develop and manufacture PCR-based assays for Panther Fusion.”
Earlier, Diagenode had partnered with Hologic in developing Panther Fusion assays for group B Streptococcus and Bordetella.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, the company played a major role in epigenetics with a strong portfolio of devices, kits, reagents, antibodies, and services to facilitate DNA and RNA analysis.
Diagenode founder and CEO Didier Allaer said: “We are very pleased that the Diagenode team will become part of Hologic’s diagnostic business.
“Our businesses are highly complementary, and we are excited that Hologic’s commercial resources and leadership in molecular automation will enable us to offer our assay menu more broadly.”
The deal is in line with Hologic’s tuck-in M&A strategy, leverages its automation capabilities, and offers better potential for growth.
Last month, Hologic completed the $230m acquisition of Biotheranostics, which develops and sells two highly differentiated molecular diagnostic tests, Breast Cancer Index (BCI) and CancerTYPE ID (CTID), for breast and metastatic cancers respectively.
The purchase of Biotheranostics, along with the latest acquisition, will continue to expand Hologic’s base diagnostics business and expedite growth post-Covid-19.
In January, Hologic acquired biopsy site markers and localisation technologies developer SOMATEX Medical Technologies in a deal valued at approximately $64m.
